KDU-691

Research use only, not for human use.

KDU-691 is a potent, selective, orally active parasite PI4K inhibitor.

KDU-691 is a potent, selective, orally active parasite PI4K inhibitor with IC50 of 1.5 nM for P. vivax PI4K (PvPI4K); shows IC50 of 58 nM, 36 nM and 196 nM against P. falciparum (Pf, boold stages), P. yoelii (Py, schizont) and P. cynomolgi (Pc, hypnozoites) respectively; shows fully protective effect against P. cynomolgi sporozoites in animal models.

——

During the 5 days of dosing, no major weight changes are observed in the animals that receive KDU691 as prophylactic treatment (group 691-proph). From the fourth day of dosing, the animals that are treated with KDU691 show a transient yellow skin color. The KDU691 radical-cure group (group 691-RC) becomes blood-stage positive again at 31.8 days p.i. (range, 31 to 32 days). Clinical chemistry analysis of the group 691-RC monkeys reveals that bilirubin levels accumulate during the 5-day radical-cure treatment with KDU691.

KDU691

PI3K/Akt/mTOR signaling

PI4K

PI4K

Infection

——

1513879-19-0

419.864

C22H18ClN5O2

>98% (HPLC)

DMSO : 150 mg/mL. 357.26 mM

ClC1=CC=C(N(C(C2=CN3C(C=N2)=NC=C3C4=CC=C(C(NC)=O)C=C4)=O)C)C=C1

N-(4-Chlorophenyl)-N-methyl-3-[4-[(methylamino)carbonyl]phenyl]imidazo[1,2-a]pyrazine-6-carboxamide

(-20℃)

With Ice Pack

≥ 2 years